Sign in to view content

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial

Eric W Schneider, MD

Video
Published 2023

Related

Episode 191: Dr. Maria Berrocal on EnVision Summit and Diabetic Vitrectomy Revisited
Jayanth Sridhar, MD
Member Podcasts
Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022

Category: Diabetic Retinopathy

See more